Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
52 Week high
52 Week low
InvestorPlace • 3 days ago • INCY3 Biotech Stocks That Should Be on Every Investor's Radar This Fall
Zacks Investment Research • 4 days ago • INCYIncyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
Market Watch • 5 days ago • INCYIncyte shares drop after FDA approves GSK's competing blood-cancer treatment
Zacks Investment Research • 23 days ago • INCYWhy Is Incyte (INCY) Down 0.7% Since Last Earnings Report?
Seeking Alpha • about 2 months ago • INCYIncyte Corporation (INCY) Q2 2023 Earnings Call Transcript
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.